ENVB
Enveric Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.41
+2.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.38
From 52W high−86.35%
Volume29823.00
Market cap$6.31M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.38
From 52W high
−86.35%
Volume
29823.00
Market cap
$6.31M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
39.3
MomentumView details →
1D Return
+2.17%
YTD Return
−62.53%
SummaryUpdated Jun 1, 2026
Enveric Biosciences, Inc. (NASDAQ:ENVB) is a pharmaceutical company founded in 2015 and headquartered in Naples, Florida. The company went public on May 4, 2015, and operates in the biotechnology sector with a focus on developing cannabinoid-based medicines for cancer care and related therapeutic applications. As a clinical-stage pharmaceutical company, Enveric has no current revenue and is in the research and development phase of bringing its drug candidates through regulatory approval processes.
Similar companies
Latest newsMore news →
Enveric Biosciences raised $5.0 million in gross proceeds from a private placement and $1.5 million from warrant exercises during Q2 2026, with potential additional proceeds of $8.9 million from full warrant exercise.67d agoEnveric Biosciences reported a net loss of $3.0 million for Q2 2026, compared to a net loss of $2.5 million in Q2 2025, with cash on hand of $8.3 million as of June 30, 2026.67d agoEnveric Biosciences announced new preclinical data confirming the non-hallucinogenic profile of its lead psychiatric drug candidate EB-003.76d ago